Literature DB >> 33098996

Local delivery of CAR T cells targeting fibroblast activation protein is safe in patients with pleural mesothelioma: first report of FAPME, a phase I clinical trial.

S Hiltbrunner1, C Britschgi1, P Schuberth1, L Bankel1, T D L Nguyen-Kim2, P Gulati3, W Weder4, I Opitz4, O Lauk5, C Caviezel5, H Bachmann1, A Tabor6, P Schröder6, A Knuth1, C Münz3, R Stahel7, O Boyman8, C Renner9, U Petrausch10, A Curioni-Fontecedro11.   

Abstract

Entities:  

Mesh：

Year:  2020        PMID： 33098996     DOI： 10.1016/j.annonc.2020.10.474

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  14 in total

Review 1.  Advances in CAR-T Cell Genetic Engineering Strategies to Overcome Hurdles in Solid Tumors Treatment.

Authors:  Alain E Andrea; Andrada Chiron; Sarah Mallah; Stéphanie Bessoles; Guillaume Sarrabayrouse; Salima Hacein-Bey-Abina
Journal:  Front Immunol       Date:  2022-02-08       Impact factor: 7.561

Review 2.  Immunotherapy approaches for malignant pleural mesothelioma.

Authors:  Dean A Fennell; Sean Dulloo; James Harber
Journal:  Nat Rev Clin Oncol       Date:  2022-07-01       Impact factor: 65.011

Review 3.  The dynamic facets of the cardiac stroma: from classical markers to omics and translational perspectives.

Authors:  Vittorio Picchio; Antonella Bordin; Erica Floris; Claudia Cozzolino; Xhulio Dhori; Mariangela Peruzzi; Giacomo Frati; Elena De Falco; Francesca Pagano; Isotta Chimenti
Journal:  Am J Transl Res       Date:  2022-02-15       Impact factor: 4.060

Review 4.  CAR T-cell therapy for pleural mesothelioma: Rationale, preclinical development, and clinical trials.

Authors:  Navin K Chintala; David Restle; Hue Quach; Jasmeen Saini; Rebecca Bellis; Michael Offin; Jason Beattie; Prasad S Adusumilli
Journal:  Lung Cancer       Date:  2021-05-05       Impact factor: 6.081

Review 5.  Critical Role of Synovial Tissue-Resident Macrophage and Fibroblast Subsets in the Persistence of Joint Inflammation.

Authors:  Samuel Kemble; Adam P Croft
Journal:  Front Immunol       Date:  2021-09-03       Impact factor: 7.561

Review 6.  Validating Cell Surface Proteases as Drug Targets for Cancer Therapy: What Do We Know, and Where Do We Go?

Authors:  Emile Verhulst; Delphine Garnier; Ingrid De Meester; Brigitte Bauvois
Journal:  Cancers (Basel)       Date:  2022-01-26       Impact factor: 6.639

Review 7.  Highlights of Strategies Targeting Fibroblasts for Novel Therapies for Rheumatoid Arthritis.

Authors:  Cong-Qiu Chu
Journal:  Front Med (Lausanne)       Date:  2022-02-17

Review 8.  Pathological Characterization of Tumor Immune Microenvironment (TIME) in Malignant Pleural Mesothelioma.

Authors:  Francesca Napoli; Angela Listì; Vanessa Zambelli; Gianluca Witel; Paolo Bironzo; Mauro Papotti; Marco Volante; Giorgio Scagliotti; Luisella Righi
Journal:  Cancers (Basel)       Date:  2021-05-24       Impact factor: 6.639

Review 9.  Biological basis for novel mesothelioma therapies.

Authors:  Joanna Obacz; Henry Yung; Marie Shamseddin; Emily Linnane; Xiewen Liu; Arsalan A Azad; Doris M Rassl; David Fairen-Jimenez; Robert C Rintoul; Marko Z Nikolić; Stefan J Marciniak
Journal:  Br J Cancer       Date:  2021-07-05       Impact factor: 9.075

Review 10.  A deep insight into CRISPR/Cas9 application in CAR-T cell-based tumor immunotherapies.

Authors:  Ehsan Razeghian; Mahyuddin K M Nasution; Heshu Sulaiman Rahman; Zhanna R Gardanova; Walid Kamal Abdelbasset; Surendar Aravindhan; Dmitry O Bokov; Wanich Suksatan; Pooria Nakhaei; Siavash Shariatzadeh; Faroogh Marofi; Mahboubeh Yazdanifar; Somayeh Shamlou; Roza Motavalli; Farhad Motavalli Khiavi
Journal:  Stem Cell Res Ther       Date:  2021-07-28       Impact factor: 6.832
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.